Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Vital KSK Holdings, Inc. ( (JP:3151) ) is now available.
Vital KSK Holdings, Inc. has announced that its subsidiary, MEDLEAP PHARMA COMPANY LIMITED, is initiating a Phase II clinical trial in Japan for Ferric Maltol, a new drug candidate for treating Pulmonary Arterial Hypertension (PAH). This advancement marks a significant step in the clinical development program, moving from preclinical to Phase II trials, and aligns with both European and Japanese guidelines recommending iron supplementation for PAH patients with iron deficiency anemia.
The most recent analyst rating on (JP:3151) stock is a Hold with a Yen1340.00 price target. To see the full list of analyst forecasts on Vital KSK Holdings, Inc. stock, see the JP:3151 Stock Forecast page.
More about Vital KSK Holdings, Inc.
Vital KSK Holdings, Inc. operates in the pharmaceutical industry, focusing on the development of innovative treatments. Its subsidiary, MEDLEAP PHARMA COMPANY LIMITED, is involved in advancing drug candidates for conditions such as Pulmonary Arterial Hypertension.
Average Trading Volume: 126,583
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen56.87B
For an in-depth examination of 3151 stock, go to TipRanks’ Overview page.